| Recruiting | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer NCT07287150 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response NCT07142551 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Not Yet Recruiting | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium NCT07414940 | University College, London | Phase 1 / Phase 2 |
| Recruiting | Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC NCT07476001 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Not Yet Recruiting | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer NCT07365995 | BioNTech SE | Phase 3 |
| Recruiting | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT06842498 | Kyntra Bio | Phase 2 |
| Not Yet Recruiting | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy NCT07423117 | IntoCell, Inc | Phase 1 |
| Recruiting | A Phase I Trial of A-CAR032 in Participants With mCRPC NCT07344311 | Shanghai AbelZeta Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer NCT07339267 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast C NCT07288359 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostat NCT07244341 | Daiichi Sankyo | Phase 1 |
| Recruiting | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve M NCT07213674 | Amgen | Phase 3 |
| Recruiting | A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) NCT07103018 | K36 Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castrat NCT07189403 | Daiichi Sankyo | Phase 1 |
| Not Yet Recruiting | Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets NCT07172126 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | The COSMYC Trial (COmbined Suppression of MYC) NCT06922318 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Suspended | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cyt NCT07025512 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostat NCT07093801 | Novartis Pharmaceuticals | — |
| Recruiting | Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer NCT06738303 | Case Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT06866795 | Geode Therapeutics Inc. | Phase 1 |
| Recruiting | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer NCT07005154 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Recruiting | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Sub NCT06830850 | Atridia Pty Ltd. | Phase 1 |
| Recruiting | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer NCT06533644 | Syncromune, Inc. | Phase 2 |
| Recruiting | Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 NCT06972628 | Ebrahim S Delpassand | Phase 2 |
| Recruiting | Post Marketing Study on Pluvicto in Korea NCT06514521 | Novartis Pharmaceuticals | — |
| Recruiting | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer NCT06866938 | Hospices Civils de Lyon | Phase 2 |
| Recruiting | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC NCT06895811 | Shanghai Changzheng Hospital | Phase 1 |
| Recruiting | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Partic NCT06764485 | Celgene | Phase 3 |
| Recruiting | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06879041 | AstraZeneca | Phase 1 |
| Active Not Recruiting | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT06909825 | Fusion Pharmaceuticals Inc. | Phase 2 |
| Recruiting | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage NCT06439225 | Canadian Cancer Trials Group | Phase 3 |
| Recruiting | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With NCT06691984 | Amgen | Phase 3 |
| Recruiting | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06568562 | University of Utah | Phase 2 |
| Recruiting | Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC NCT06971211 | Jianbin Bi | Phase 2 |
| Recruiting | Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer NCT06228053 | Syntrix Biosystems, Inc. | Phase 2 |
| Recruiting | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Tr NCT06531499 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC NCT06193486 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Ca NCT06629779 | Pfizer | Phase 3 |
| Recruiting | Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT06401980 | Swiss Cancer Institute | Phase 2 |
| Withdrawn | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer NCT06329830 | Baptist Health South Florida | Phase 1 / Phase 2 |
| Recruiting | Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer NCT06517719 | Novartis Pharmaceuticals | — |
| Recruiting | Study With [225Ac]Ac-FL-020 in mCRPC Participants NCT06492122 | Full-Life Technologies GmbH | Phase 1 |
| Recruiting | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) NCT06520345 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 |
| Recruiting | Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Prog NCT06529549 | Sun Yat-sen University | — |
| Recruiting | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer NCT06480110 | Rigshospitalet, Denmark | Phase 1 / Phase 2 |
| Active Not Recruiting | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer NCT06303713 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC NCT06383052 | Norroy Bioscience Co., LTD | Phase 1 / Phase 2 |
| Active Not Recruiting | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cance NCT06229366 | Eli Lilly and Company | Phase 1 |
| Recruiting | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan NCT06099093 | Brigham and Women's Hospital | Phase 4 |
| Recruiting | Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion NCT06029998 | University of Utah | Phase 2 |
| Recruiting | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adul NCT06318273 | AbbVie | Phase 1 |
| Active Not Recruiting | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCR NCT06402331 | Fusion Pharmaceuticals Inc. | Phase 2 |
| Recruiting | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC NCT06228404 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Unknown | Intestinal Akkermansia Muciniphila in Prostate Cancer NCT06242509 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With O NCT06380738 | AstraZeneca | — |
| Unknown | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors NCT06221774 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1 / Phase 2 |
| Completed | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (m NCT06136598 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | PROCARE - PROstate Cancer Real World Evidence Registry NCT06835218 | UroTrials Company (GmbH) | — |
| Enrolling By Invitation | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease NCT05570994 | British Columbia Cancer Agency | Phase 1 / Phase 2 |
| Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients NCT06155084 | Hinova Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Recruiting | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC NCT06100705 | Yale University | Phase 2 |
| Recruiting | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer NCT05766371 | University of California, San Francisco | Phase 2 |
| Active Not Recruiting | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC NCT05682443 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Completed | Study of INKmune in Patients With mCRPC (CaRe Prostate) NCT06056791 | Inmune Bio, Inc. | Phase 1 / Phase 2 |
| Recruiting | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC NCT05762536 | Erasmus Medical Center | Phase 2 |
| Active Not Recruiting | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer NCT06104449 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer NCT06067841 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | PRostate Olaparib Real World Evidence Study NCT06031805 | AstraZeneca | — |
| Terminated | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. NCT05917470 | Oncternal Therapeutics, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affect NCT06052306 | Bayer | Phase 1 |
| Unknown | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Pros NCT05955209 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metas NCT05613894 | University of Utah | Phase 1 |
| Recruiting | 64Cu-GRIP B in Patients With Advanced Malignancies NCT05888532 | Rahul Aggarwal | Phase 1 / Phase 2 |
| Recruiting | FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 | Parabilis Medicines, Inc. | Phase 1 / Phase 2 |
| Unknown | Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) NCT05823402 | BAMF Health | N/A |
| Unknown | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer NCT06250244 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Recruiting | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - NCT05720130 | AdvanCell Pty Limited | Phase 1 / Phase 2 |
| Completed | Phase 0/1 Study of 212Pb-NG001 in mCRPC NCT05725070 | ARTBIO Inc. | EARLY_Phase 1 |
| Terminated | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT05673109 | Accutar Biotechnology Inc | Phase 1 |
| Completed | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Soli NCT05700669 | Valerio Therapeutics | Phase 1 / Phase 2 |
| Completed | Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer NCT05544227 | Williams Cancer Foundation | Phase 1 |
| Recruiting | 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer NCT05603559 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Recruiting | 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer NCT05613738 | Peking Union Medical College Hospital | N/A |
| Terminated | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers NCT05588609 | Merus B.V. | Phase 2 |
| Unknown | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix NCT05558956 | BAMF Health | EARLY_Phase 1 |
| Completed | Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) NCT03454750 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb NCT05521412 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Recruiting | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) NCT05519449 | Janux Therapeutics | Phase 1 |
| Terminated | A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese M NCT05301062 | Bayer | — |
| Active Not Recruiting | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cance NCT05383079 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Terminated | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant NCT05489991 | Tceleron Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tu NCT05489211 | AstraZeneca | Phase 2 |
| Withdrawn | Phase 1 Study of ATRS-2002 in Healthy Male Adults NCT04879589 | Syneos Health | Phase 1 |
| Recruiting | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application NCT05458544 | FutureChem | Phase 1 / Phase 2 |
| Terminated | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistan NCT05405439 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT05533203 | Shanghai Humantech Biotechnology Co. Ltd | Phase 1 |
| Completed | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Re NCT05457257 | AstraZeneca | Phase 4 |
| Recruiting | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850 | Blue Earth Therapeutics Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer NCT05340374 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Recruiting | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537 | Vadim S Koshkin | Phase 1 / Phase 2 |
| Terminated | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer NCT05156905 | University of California, San Diego | Phase 1 |
| Active Not Recruiting | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer NCT04754191 | University of Utah | Phase 2 |
| Unknown | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation NCT05327621 | Sun Yat-sen University | Phase 2 |
| Completed | MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer NCT05127850 | University of California, San Francisco | N/A |
| Active Not Recruiting | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer NCT05245006 | Robert Flavell, MD, PhD | Phase 1 |
| Terminated | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT05241613 | Accutar Biotechnology Inc | Phase 1 |
| Completed | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastat NCT05081193 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer NCT05011188 | Rahul Aggarwal | Phase 1 / Phase 2 |
| Terminated | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resi NCT05177770 | Coherus Oncology, Inc. | Phase 2 |
| Terminated | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT05369000 | Lava Therapeutics | Phase 1 |
| Active Not Recruiting | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant NCT05219500 | Fusion Pharmaceuticals Inc. | Phase 2 |
| Completed | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metasta NCT05252364 | Hinova Pharmaceuticals Aus Pty Ltd | Phase 1 |
| Terminated | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer NCT05124795 | Immunic AG | Phase 1 |
| Unknown | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation NCT05262608 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN NCT05125016 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors ( NCT05116579 | Sun Yat-sen University | — |
| Completed | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastat NCT05005728 | Xencor, Inc. | Phase 2 |
| Recruiting | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer NCT04986423 | Zenith Epigenetics | Phase 2 |
| Active Not Recruiting | Abemaciclib With or Without Atezolizumab for mCRPC NCT04751929 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Completed | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic NCT04869488 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Active Not Recruiting | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC NCT04846478 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting NCT04844749 | Veru Inc. | Phase 3 |
| Active Not Recruiting | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate NCT05171816 | AstraZeneca | Phase 3 |
| Recruiting | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer NCT04729114 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Terminated | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets NCT04853498 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) NCT04925284 | Exelixis | Phase 1 |
| Terminated | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC NCT04629781 | Swiss Cancer Institute | Phase 1 |
| Completed | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer NCT04887506 | Tavanta Therapeutics | Phase 3 |
| Recruiting | ProsTIC Registry of Men Treated With PSMA Theranostics NCT04769817 | Peter MacCallum Cancer Centre, Australia | — |
| Terminated | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma NCT04740034 | Amgen | Phase 1 |
| Terminated | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC NCT04634344 | Dizal Pharmaceuticals | Phase 1 |
| Completed | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib NCT04676334 | pharmaand GmbH | Phase 3 |
| Completed | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prost NCT04703920 | University of Michigan Rogel Cancer Center | Phase 1 |
| Active Not Recruiting | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment NCT04647526 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Phase 3 |
| Completed | Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic NCT04666129 | Sumitomo Pharma America, Inc. | Phase 1 |
| Terminated | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 | Exelixis | Phase 1 |
| Completed | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer NCT04408924 | Eli Lilly and Company | Phase 2 |
| Terminated | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT04631601 | Amgen | Phase 1 / Phase 2 |
| Terminated | A Study of FT-7051 in Men With MCRPC NCT04575766 | Novo Nordisk A/S | Phase 1 |
| Completed | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT04676607 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Terminated | Abiraterone Acetate in Combination With Tildrakizumab NCT04458311 | Institute of Cancer Research, United Kingdom | Phase 1 / Phase 2 |
| Completed | [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. NCT04509557 | FutureChem | Phase 1 |
| Terminated | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects Wi NCT04556617 | Opna Bio LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer NCT04109729 | University of Utah | Phase 1 |
| Unknown | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation NCT04486937 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 / Phase 2 |
| Unknown | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate C NCT04419402 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Terminated | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patie NCT04237584 | MANA RBM | Phase 3 |
| Unknown | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adeno NCT04586543 | László Mangel | Phase 2 |
| Active Not Recruiting | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer NCT04253262 | Brown University | Phase 1 / Phase 2 |
| Completed | A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants NCT04268628 | Janssen-Cilag Farmaceutica Ltda. | — |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Charact NCT04104893 | VA Office of Research and Development | Phase 2 |
| Completed | PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate NCT04256993 | Bayer | — |
| Completed | 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies NCT04158245 | Tulane University | Phase 2 |
| Unknown | Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer NCT04225910 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Completed | 3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer NCT04000776 | Université de Sherbrooke | — |
| Completed | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patien NCT04179396 | pharmaand GmbH | Phase 1 |
| Completed | Checkpoint Inhibitors and SBRT for MCRPC NCT05655715 | Herlev and Gentofte Hospital | Phase 2 |
| Terminated | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer NCT04227275 | Tceleron Therapeutics, Inc. | Phase 1 |
| Terminated | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Can NCT04179864 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Completed | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combinati NCT04068896 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Recruiting | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas NCT04104776 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC NCT04060394 | Laekna Limited | Phase 1 / Phase 2 |
| Completed | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) NCT03658447 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Completed | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel NCT03835533 | Parker Institute for Cancer Immunotherapy | Phase 1 |
| Terminated | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castra NCT03531827 | National Cancer Institute (NCI) | Phase 2 |
| Completed | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers NCT03829436 | Tempest Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors NCT03845166 | Exelixis | Phase 1 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC NCT03792841 | Amgen | Phase 1 |
| Terminated | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC NCT03770455 | Jodi Layton, MD | Phase 2 |
| Terminated | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate NCT03752099 | Veru Inc. | Phase 1 / Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Unknown | 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer NCT04188587 | Nanjing First Hospital, Nanjing Medical University | Phase 2 |
| Completed | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations NCT03570619 | University of Michigan Rogel Cancer Center | Phase 2 |
| Unknown | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer NCT03692663 | Allife Medical Science and Technology Co., Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate NCT03732820 | AstraZeneca | Phase 3 |
| Completed | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistan NCT03641560 | Astellas Pharma Inc | Phase 4 |
| Completed | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resist NCT03414034 | Cardiff Oncology | Phase 2 |
| Completed | Study to Evaluate CCS1477 in Advanced Tumours NCT03568656 | CellCentric Ltd. | Phase 1 / Phase 2 |
| Completed | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) NCT03493945 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers NCT03454451 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer NCT03780075 | Peking Union Medical College Hospital | Phase 1 |
| Completed | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch NCT03778047 | Hinova Pharmaceuticals Inc. | Phase 1 |
| Completed | Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC NCT03437941 | Corcept Therapeutics | Phase 1 / Phase 2 |
| Completed | A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalut NCT03328364 | Astellas Pharma a/s | — |
| Unknown | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer NCT03403595 | Peking Union Medical College Hospital | Phase 1 |
| Terminated | Combination Study of AZD5069 and Enzalutamide. NCT03177187 | Institute of Cancer Research, United Kingdom | Phase 1 / Phase 2 |
| Completed | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics NCT03776968 | Hinova Pharmaceuticals Inc. | Phase 1 |
| Active Not Recruiting | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cance NCT03230734 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Terminated | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With NCT03137758 | Pellficure Pharmaceuticals, Inc | Phase 1 |
| Terminated | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy NCT03042312 | Endocyte | Phase 2 |
| Completed | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant NCT02975934 | pharmaand GmbH | Phase 3 |
| Completed | Tissue Predictors of Abiraterone Benefit NCT03176381 | Tianjin Medical University Second Hospital | — |
| Unknown | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC NCT03085966 | Shanghai AbelZeta Ltd. | Phase 1 / Phase 2 |
| Completed | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombina NCT02952534 | pharmaand GmbH | Phase 2 |
| Completed | A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. NCT03774056 | Hinova Pharmaceuticals Inc. | Phase 1 |
| Completed | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Res NCT02987543 | AstraZeneca | Phase 3 |
| Completed | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer NCT02991911 | MedImmune LLC | Phase 1 |
| Completed | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostat NCT02711956 | Zenith Epigenetics | Phase 1 / Phase 2 |
| Terminated | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumo NCT02744287 | Regeneron Pharmaceuticals | Phase 1 |
| Recruiting | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK- NCT02861573 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)( NCT02787005 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT02705469 | Zenith Epigenetics | Phase 1 |
| Completed | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer NCT02566772 | Taiho Oncology, Inc. | Phase 1 |
| Completed | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezoli NCT02655822 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Completed | Optimizing Abiraterone Therapy NCT02426333 | Radboud University Medical Center | — |
| Terminated | A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or NCT02441517 | Astellas Pharma Global Development, Inc. | Phase 4 |
| Completed | Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Res NCT02471469 | Radboud University Medical Center | — |
| Completed | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT02495974 | Astellas Pharma Europe Ltd. | — |
| Completed | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded P NCT02405858 | Janssen Pharmaceutical K.K. | Phase 4 |
| Completed | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatm NCT02288247 | Astellas Pharma Europe Ltd. | Phase 3 |
| Completed | Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resis NCT02424448 | The Christie NHS Foundation Trust | — |
| Completed | Sequencing Abiraterone and Enzalutamide in mCRPC NCT02125357 | British Columbia Cancer Agency | Phase 2 |
| Completed | Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic NCT02141438 | Bayer | — |
| Completed | Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer NCT04056754 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant NCT02123758 | Aragon Pharmaceuticals, Inc. | Phase 1 |
| Completed | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prost NCT02111577 | SOTIO a.s. | Phase 3 |
| Completed | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer NCT02116582 | Astellas Pharma Europe B.V. | Phase 4 |
| Completed | Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer NCT02044354 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. NCT01972217 | AstraZeneca | Phase 2 |
| Completed | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment NCT02047253 | University of Alabama at Birmingham | Phase 2 |
| Completed | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients NCT02091531 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer NCT01942837 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With M NCT01663415 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Completed | A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate NCT01650194 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Completed | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer NCT01594918 | Rahul Aggarwal | Phase 1 |
| Completed | A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer NCT01541007 | Jeffrey Yachnin M.D., PhD. | Phase 2 |
| Completed | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate NCT01517802 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. NCT00428220 | Pfizer | N/A |
| Approved For Marketing | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Pr NCT01606982 | Astellas Pharma Global Development, Inc. | — |
| Available | Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) NCT05650476 | Pfizer | — |
| Approved For Marketing | Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combinatio NCT05401214 | Janssen Research & Development, LLC | — |